CN Patent

CN120097995A — 甲基修饰酶的调节剂、其组合物和用途

Assigned to Constellation Pharmaceuticals Inc · Expires 2025-06-06 · 1y expired

What this patent protects

提供了式(I)的新颖化合物：和其药学上可接受的盐，其可用于治疗与甲基修饰酶相关的各种疾病、病症或病状。还提供了包含所述式(I)的新颖化合物、其药学上可接受的盐的药物组合物，以及所述药物组合物用于治疗与甲基修饰酶相关的一种或多种疾病、病症或病状的方法。

USPTO Abstract

提供了式(I)的新颖化合物：和其药学上可接受的盐，其可用于治疗与甲基修饰酶相关的各种疾病、病症或病状。还提供了包含所述式(I)的新颖化合物、其药学上可接受的盐的药物组合物，以及所述药物组合物用于治疗与甲基修饰酶相关的一种或多种疾病、病症或病状的方法。

Drugs covered by this patent

Xiidra (LIFITEGRAST) · Bausch Health

Patent Metadata

Patent number: CN120097995A
Jurisdiction: CN
Classification: —
Expires: 2025-06-06
Drug substance claim: No
Drug product claim: No
Assignee: Constellation Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.